Compare VNRX & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNRX | SNGX |
|---|---|---|
| Founded | N/A | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2M | 7.7M |
| IPO Year | 2012 | 2006 |
| Metric | VNRX | SNGX |
|---|---|---|
| Price | $0.17 | $0.36 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $13.62 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 169.6K |
| Earning Date | 11-12-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.00 | ★ 57.03 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,727,384.00 | $119,371.00 |
| Revenue This Year | $57.67 | N/A |
| Revenue Next Year | $240.52 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 40.04 | N/A |
| 52 Week Low | $0.13 | $0.32 |
| 52 Week High | $3.26 | $3.39 |
| Indicator | VNRX | SNGX |
|---|---|---|
| Relative Strength Index (RSI) | 22.79 | 24.83 |
| Support Level | $0.15 | N/A |
| Resistance Level | $0.18 | $0.82 |
| Average True Range (ATR) | 0.02 | 0.02 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 0.32 | 39.05 |
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).